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Abstract
Colistin is a re-emerging old antibiotic that is used to treat multidrug-resistant infections in critically ill patients. It corresponds to a
mixture of at least 30 different compounds administered as inactive derivatives. Therefore, colistin pharmacokinetics are quite difﬁcult
to investigate and complex to predict. However speciﬁc chromatographic methods have been made available in recent years, leading to
a series of modern pharmacokinetic studies after intravenous administration of the prodrug to critical-care patients; these have been
conducted by a few groups and have only been recently published. The objective of this article was to conduct a critical review of these
very informative modern pharmacokinetic studies and to provide prospective thoughts.
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Introduction
After being abandoned in the early 1980s because of
reported nephrotoxicity and neurotoxicity, colistin is having
a second life as a ‘salvage’ treatment against multiresistant
Gram-negative bacteria such as Pseudomonas and Acinetobac-
ter in critically ill patients [1,2]. Colistin is composed of at
least 30 different polymyxin compounds, mainly colistin A
and B, and it is administered intravenously as a complex mix
of colistin methanesulphonate (CMS) derivatives. Initial phar-
macokinetic studies relied on bioassays, which are still used
in some institutions. However, because colistin is adminis-
tered as a prodrug that can be easily converted into the
active compound during storage or sample handling, accurate
pharmacokinetic studies require speciﬁc analytical assays, and
bioassays should therefore no longer be used [1]. Chromato-
graphic procedures using HPLC with post-derivation ﬂuori-
metric detection [3] or liquid chromatography–tandem mass
spectrometry (LC-MS/MS) [4,5] have only relatively recently
been developed, and used by several groups in order to
complete a series of major modern pharmacokinetic studies.
Several extensive reviews have been published on colistin
in general and on its pharmacokinetics in particular [1,6,7].
The objective of the present article was not simply to update
the previous reports, but also to conduct a critical review
with prospective thoughts and a focus on the most recent
pharmacokinetic studies, published during the last few years
or months, or not yet published but only presented at inter-
national meetings. Furthermore, although CMS may be aero-
solized, especially in patients with cystic ﬁbrosis, this last
mode of administration raises a number of speciﬁc biophar-
maceutical questions that have been recently characterized in
rats [8]. It will not be considered throughout this review,
which will be focused on colistin pharmacokinetics in critical-
care patients treated intravenously with CMS.
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Pharmacokinetic Studies in Rats
An initial pharmacokinetic study in rats, using a novel speciﬁc
HPLC assay, was conducted in 2003, after direct intravenous
administration of colistin, allowing the estimation of primary
pharmacokinetic parameters [9]. The colistin volume of dis-
tribution was estimated to 0.50 ± 0.06 L/kg, indicating limited
extravascular distribution, consistent with its physicochemical
characteristics, including molecular mass and hydrophilicity.
Protein binding, which has an effect on distribution and elimi-
nation, was determined by equilibrium dialysis, as non-spe-
ciﬁc adsorption on the membranes precluded the use of
ultraﬁltration. The colistin unbound fraction (fu) varied
between 43% and 45% as concentration ranged from 1.5 mg/
mL to 6.0 mg/mL. However, colistin A was more extensively
bound (fu 36%) than colistin B (fu 52%). Colistin clear-
ance was estimated to be 5.2 ± 0.4 mL/min/kg, with <1% of
colistin being excreted unchanged in urine. The derived
clearance value (CLR = 0.010 ± 0.008 mL/min/kg) was much
lower than the expected renal clearance by glomerular ﬁltra-
tion, which, assuming an average fu of 0.44 and a glomerular
ﬁltration rate (GFR) of 5.2 mL/min/kg in rats, should be
equal to 2.3 mL/min/kg. This low renal clearance suggested
extensive tubular reabsorption, which was later conﬁrmed
by the same group and attributed to active transport systems
[10]. As another consequence of this very low renal clear-
ance, one may conclude that colistin non-renal clearance is
almost equal to its total clearance and much lower than
hepatic blood ﬂow in rats (72–95 mL/min/kg), suggesting a
low hepatic extraction ratio. Therefore, colistin clearance
should be independent of hepatic blood ﬂow but should vary
with protein binding and hepatic intrinsic clearance. How-
ever, as colistin is probably not extensively bound to plasma
proteins, its hepatic intrinsic clearance and therefore enzy-
matic activity could mainly determine its clearance value.
Finally, the colistin elimination half-life in rats was
74.6 ± 13.2 min.
One year later, the same group conducted a second phar-
macokinetic study in rats, but after intravenous administra-
tion of CMS at a dose of 15 mg/kg [11]. The same speciﬁc
HPLC assay [3] was used, allowing direct comparisons
between the two studies. However, CMS concentrations
were not measured directly, but were obtained from the dif-
ference between colistin levels determined in samples after
and before hydrolysis. Therefore, the authors mentioned
that pharmacokinetic parameters for CMS may best be con-
sidered as hybrid parameters for CMS and the partially sulp-
homethylated derivatives. In that study, the CMS volume of
distribution was estimated to be 0.30 ± 0.06 L/kg, corre-
sponding almost exactly to extracellular ﬂuid volume, and to
about 60% of the value determined for colistin. CMS protein
binding was not estimated, as ultraﬁltration is not recom-
mended, for reasons previously explained, and equilibrium
dialysis cannot be used, because of unavoidable spontaneous
hydrolysis during the process. CMS elimination was charac-
terized by a total clearance of 11.7 ± 1.8 mL/min/kg. The
fraction of the CMS dose recovered in urine was estimated
to be 61% ± 14%, and 33% ± 15% was recovered as colistin.
However, given the low urinary recovery of colistin (<1%) in
rats treated directly with this active moiety [9], the authors
concluded that most of the colistin measured in urine after
CMS administration was the result of post-excretion CMS
hydrolysis. Accordingly, CMS renal clearance was estimated
with the summed amount of CMS and colistin recovered in
urine. CMS renal clearance (7.2 ± 2.2 mL/min/kg) was only
slightly greater than GRF in rats (5.2 mL/min/kg), and this dif-
ference could be within the limits of experimental uncer-
tainty. Therefore, except in cases of extensive plasma
protein binding, CMS would undergo modest net tubular
secretion, as suggested by the authors. CMS non-renal clear-
ance was estimated to be 4.9 mL/min/kg on average, and,
assuming that colistin clearance was the same after this CMS
administration and after direct injection [9], it was possible
to estimate that only 6.8% of the CMS dose was converted
into colistin on average. Finally, the CMS elimination half-life
(23.6 ± 3.9 min) was signiﬁcantly shorter than that of colistin
(55.7 ± 19.3 min), indicating that colistin disposition is not
rate-limited by its formation. However, colistin concentra-
tions reached a peak very early (after 5 min in three rats
and after 10 min in the remaining two), which is usually a
characteristic of metabolites with formation rate-limited
elimination [12]. Therefore, this early peak occurrence for a
‘metabolite’ with an elimination that is not rate-limited by its
formation is unusual and difﬁcult to explain.
More recently, a dose-ranging pharmacokinetic study was
conducted by our group, using a new LC-MS/MS assay [13].
No trend of non-linearity was observed in this large range of
doses (5–120 mg/kg), and systemic pharmacokinetic parame-
ter values were fully consistent with those previously pub-
lished by Li et al., in particular when the same dose (15 mg/
kg) was administered. Using the same calculation and hypoth-
esis as Li et al., we estimated that 15.5% of the CMS dose
was converted into colistin in rats on average, which is
slightly more than the value reported by these authors
(6.8%), but low enough to conﬁrm that, at least in rats, only
a limited fraction of the CMS dose is actually converted into
colistin. Interestingly, we also observed the previously
described unexpected and still unexplained early peak
appearance for a ‘metabolite’ with elimination that is not
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rate-limited by its formation. Considering that rapid hydroly-
sis of CMS in rat plasma could possibly explain this rapid
colistin appearance, we compared the relative instability of
CMS in spiked human vs. rat plasma at 37C. However, no
major difference was observed between the CMS rate of
degradation and the colistin rate of formation in rat and
human plasma (Fig. 1).
The effect of hepatic insufﬁciency on colistin pharmacoki-
netics in rats was recently investigated in our laboratory
(unpublished data, available on request). Acute hepatic failure
was obtained by intraperitoneal administration of CCl4 and
conﬁrmed by alanine aminotransferase and aspartate amino-
transferase determinations. Control rats and rats with hepa-
tic failure (n = 6 per group) were treated 24 h after CCl4
administration, either with CMS (15 mg/kg administered
intravenously) or with colistin (1.5 mg/kg administered sub-
cutaneously). No signiﬁcant differences were observed
between CMS and colistin pharmacokinetic parameters esti-
mated in rats with hepatic failure and control animals after
CMS or colistin administration (Fig. 2). However, the possi-
bility cannot be excluded that this absence of effect was
attributable to the inability of the experimental model to
reproduce and predict what would happen in patients with
hepatic insufﬁciency.
Modern Pharmacokinetic Studies in
Humans After intravenous Administration
of CMS
A pharmacokinetic study of colistin following intravenous
CMS administration to patients with cystic ﬁbrosis and using
a speciﬁc assay was published in 2003 [14]. However, as pre-
viously mentioned, CMS is most frequently aerosolized for
cystic ﬁbrosis patients, and this review is essentially focused
on critical-care patients treated intravenously with CMS. For
homogeneity purpose, CMS doses will be expressed in mil-
lions of International Units (MIU), which may not be the
most appropriate practice [15], but is at least the most
usual.
An initial pharmacokinetic study of colistin in critically ill
patients, using a chromatographic assay, was published in
2008 by Markou et al. [16]. Fourteen patients were studied
after at least 2 days of CMS treatment at a maintenance
dose of 3 MIU three times daily. Noticeably, colistin concen-
trations were not determined after the initial CMS dose, and
CMS concentrations were not assayed. Therefore, the major
reported ﬁnding was a colistin plasma peak concentration of
2.93 mg/mL, occurring on average 15 min after the end of
the 30-min infusion. However, such an early peak was not
observed in the most recent studies, and it can most likely
be explained, at least in part, by uncontrolled post-sampling
CMS degradation, as only a low percentage of CMS hydroly-
sis would have a pronounced inﬂuence on early colistin
concentrations.
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FIG. 1. Colistin methanesulphonate (CMS) disappearance vs. time at
37C in fresh human (h) and rat ( ) plasma, spiked with CMS at an
initial concentration close to 7.5 mg/mL, and corresponding colistin
appearance in human (s) and rat (d) plasma.
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FIG. 2. Colistin methanesulphonate (CMS) (d) and colistin (s)
plasma concentrations (mean ± SD) vs. time following single intrave-
nous dose (15 mg/kg) of CMS in: (a) control rats; and (b) rats with
impaired hepatic function.
32 Clinical Microbiology and Infection, Volume 18 Number 1, January 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 30–39
Therefore, in our opinion, the really ﬁrst major modern
pharmacokinetic study in critical-care patients was published
in 2009 by Plachouras et al. [17]. CMS was administered at a
dose of 3 MIU (equivalent to 240 mg of CMS) infused over
15 min every 8 h, corresponding to a very common dose,
and pharmacokinetic analysis was conducted after the ﬁrst
and fourth infusions (typically 2 · 9 samples per patient).
CMS and colistin concentrations were measured with a novel
LC-MS/MS assay [4], and a population pharmacokinetic analy-
sis was conducted. Critically ill patients (n = 18, six females
and 12 males; mean age of 63.6 years, with creatinine clear-
ance (CrCL) ranging between 41 and 126 mL/min, with a
mean value of 82.3 mL/min) were enrolled. CMS and colistin
data were analysed simultaneously with a two-compartment
model for CMS and a one-compartment model for colistin.
The pharmacokinetic parameter values obtained in this study
are presented in Table 1. The colistin elimination half-life
(typical value: 14.4 h) was much longer than that of CMS
(typical value: 2.3 h), indicating that colistin elimination is not
formation rate-limited, as already observed in rats [11].
However, as opposed to the ﬁndings of Markou et al. [16], it
took about 7 h on average before the colistin plasma peak
concentration was reached, consistent with the fact that
colistin distribution is rate-limited by its elimination, but dif-
ferent from the almost instantaneous colistin peak appear-
ance in rats. One of the most interesting characteristics of
this study was that data were collected for the ﬁrst time
after patients received the initial CMS dose. It clearly showed
that, for a typical patient, colistin concentrations should stay
below the MIC breakpoints (2 mg/mL) published by the
European Committee on Antimicrobial Susceptibility Testing
[18] after the ﬁrst few 3 MIU/8 h doses, corresponding to
what is probably the most common dosing regimen. This
observation was extremely important, as insufﬁcient antibi-
otic concentrations are likely to be responsible for increased
mortality and/or resistance development. Therefore, the
authors conducted simulations, suggesting the use of a load-
ing dose of up to 9 MIU, and then various dosing intervals
between two consecutive doses at steady state. The results
of these simulations were later conﬁrmed by another study
conducted by the same group in ten critical-care patients
who received a loading dose of 6 MIU (Friberg et al., 50th
ICAAC, 2010, A1-665). Colistin plasma concentrations above
1 mg/mL were obtained within 4 h in the majority of
patients. However, independently of the loading dose, colis-
tin plasma concentrations at steady state are determined by
the maintenance dose, and for a typical ‘Plachouras et al.
patient’, the usual 3 MIU/8 h dosing regimen would most
often lead to average colistin plasma concentrations at steady
state lower than 2 mg/mL, which may not be enough for
bacteria with reduced susceptibility to antibiotics. Another
interesting ﬁnding resulting from the slow increase in colistin
plasma concentrations with time and from the short dosing
interval (8 h) as compared with the colistin half-life (14.4 h)
TABLE 1. Previously published [17,19,22] (Gre´goire et al., 21st ECCMID, 2011, 804pp.) pharmacokinetic parameter values
(relative standard error) for colistin methanesulphonate (CMS) and colistin after intravenous administration of CMS to heal-
thy volunteers or critical-care patients
Healthy volunteer Critically ill patients
Couet et al. (22) Plachouras et al. [17] Garonzik et al. [19]
Gregoire et al. (Gre´goire
et al., 21st ECCMID,
2011, 804pp.)
Typical value
IIV (CV%)
Typical
value IIV (CV%)
Typical
value IIV (CV%)
Typical
value IIV (CV%)
CMS
CL (mL/min) 148 (5) 15 (47) 228 (10) 37 (15) 61.0 (–)
154.3a
– 107 (–) 42 (30)
Vc (L) 8.92 (6) 13.5 (45) 11.5 (5) 32 5.3 (10)
Q (mL/min) 41.4 (15) 2217 (35) 133 (12) 84 123 (13)
Vp (L) 5.1 (–) 28.9 (22) 18.7 (9) 79 29.7 (12)
CLR (mL/min) 103 (8) 16 (48) – 29.3 (9)
122.6a
– 82.8 (10)
Colistin
CL/fm (mL/min) 48.7 (15) 151.5
b (19) 59 (36) 45.3 (–)
65.9a
23 33.4 (–)
V/fm (L) 12.4 (15) 19 (53) 189
b (12) 45.1 (6) 48 7.2 (11)
CLR/fm (mL/min) 1.9 (19) 56 (49) 7.0
29.4a
2.1 (17) 63 (50)
CL, clearance of CMS; CL/fm, clearance of formed colistin; CLR, renal clearance of CMS; CLR/fm, renal clearance of formed colistin; CV, coefﬁcient of variation; IIV, inter-indi-
vidual variability; Q, intercompartmental clearance for CMS; Vc, volume of distribution of central compartment for CMS; V/fm, volume of distribution of formed colistin; Vp,
volume of distribution of peripheral compartment for CMS.
aParameter value calculated from the authors’ formula for a creatinine clearance of 120 mL/min/1.73 m2.
bCL/fcoli and V/fcoli are reported instead of CL/fm and V/fm.
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was that the ﬂuctuations in colistin plasma concentrations at
steady state are limited. The authors did not observe a cor-
relation between CrCL and colistin disposition, but acknowl-
edged that this may be attributable to the limited number of
patients and relatively small range of CrCL values, with an
average of 82.3 mL/min.
The second major modern pharmacokinetic study of colis-
tin after intravenous administration of CMS to critical-care
patients was conducted on a larger scale (n = 105 patients
for 851 samples analysed), and has just been published [19].
CMS was administered as a short-term infusion every 8–
24 h. The median daily dose of colistin was 6.7 MIU (range:
2.5–13.6 MIU). Among the 105 patients, 89 were not on
renal replacement, 12 were receiving haemodialysis, three
were on continuous venovenous haemodialysis, and one was
on continuous venovenous haemoﬁltration. CrCL values ran-
ged from 0 to 169 mL/min/1.73 m2. A number of observa-
tions were similar to the ﬁndings of Plachouras et al. [17]. In
particular, the distribution of CMS and colistin was best
described by a linear model comprising, respectively, two
compartments and one compartment. Colistin plasma con-
centration vs. time proﬁles were much ﬂatter that those of
CMS, consistent with the longer colistin elimination half-life.
Average colistin steady-state plasma concentrations (Css,avg)
varied in a relatively large range (0.48–9.38 mg/mL, with a
median of 2.36 mg/mL), reﬂecting the greater variability in
patient status. Pharmacokinetic parameter values are pre-
sented in Table 1. A strong inverse trend was observed
between Css,avg and CrCL. Accordingly, CrCL was an impor-
tant covariate, not only for CMS but also for colistin. The
authors conﬁrmed that the reason why CrCL was not identi-
ﬁed as a covariate for colistin clearance in the Plachouras
et al. study was simply the narrow range of CrCL. Further-
more, data from both studies are in agreement in suggesting
that, in patients with normal or moderately impaired renal
function, the currently recommended daily doses of CMS are
not sufﬁcient to obtain reliably efﬁcacious steady-state con-
centrations of colistin. The authors proposed the following
dosing algorithm, incorporating renal function, to estimate
the CMS maintenance dose (expressed in colistin base activ-
ity) required to reach a target Css,avg (mg/mL) for colistin:
Daily dose of colistin base activity (mg) = Css,avg target ·
(1.50 · CrCL + 30) (Eqn 1)
This daily dose may be expressed in CMS MIU as follows:
Daily dose of CMS (MIU) = Css,avg target · (0.05 ·
CrCL + 1) (Eqn 2)
In these equations, CrCL is expressed in mL/min/1.73 m2.
It was conﬁrmed that CMS and colistin are efﬁciently cleared
by venovenous haemodiaﬁltration [20] or during haemodialy-
sis [21], and the algorithm was successfully adjusted to this
situation. Overall CrCL explained approximately 60% of the
variability in the ideal maintenance dose corresponding to a
target Css,avg, and the authors recommended that CMS daily
doses higher than 10 MIU should not be used.
The usefulness of starting CMS treatment with a loading
dose, as suggested by Plachouras et al. as a consequence of
the slow increase in colistin concentrations with time, was
also considered. Because the central compartment volume
for CMS was successfully modelled as a function of body
weight, the authors recommended a CMS loading dose
adjusted to body weight (using the lower of either actual or
ideal body weight), followed by a maintenance dose starting
24 h later. Accordingly, a patient with a body weight of
60 kg would require 8 MIU of CMS to reach a target con-
centration equal to 2 mg/mL, but the authors recommended
limiting the loading dose to a maximum of 10 MIU.
The ﬁrst modern pharmacokinetic study of colistin follow-
ing single-dose intravenous administration of CMS (1 MIU)
to healthy volunteers was conducted by our group [22] and
published almost simultaneously with the article of Garonzik
et al. [19]. The slow appearance of colistin in plasma was
again observed, and pharmacokinetic parameter values in
healthy volunteers (Table 1) were essentially consistent with
those previously obtained by Plachouras et al. [17] and
Garonzik et al. [19] in critical-care patients. However, for
the ﬁrst time, urine samples were collected and analysed for
CMS and colistin concentrations, in order to differentiate
between renal and non-renal CMS clearance. The data were
corrected for post-excretion hydrolysis of CMS to colistin.
Accordingly, the fraction of the CMS dose recovered after
24 h in urine was equal to 49%, but the fraction actually
excreted (fe) was estimated to be 64%. The typical value for
CMS renal clearance was 103 mL/min, whereas that for colis-
tin renal clearance was much lower (typical value of 1.9 mL/
min), consistent with the extensive tubular reabsorption
demonstrated in rats. On the assumption that the fraction of
the CMS dose not excreted unchanged (1 – fe) was totally
converted into colistin, as initially suggested by Li et al. [1], it
was possible to determine that, in healthy volunteers, about
30% of the CMS dose was converted into colistin. The ‘true’
colistin pharmacokinetic parameters values could then be
estimated, and not only the apparent pharmacokinetic
parameters (parameters divided by the fraction of the admin-
istered CMS dose eventually converted into colistin), in
order to facilitate comparisons with physiological parameter
values such as extracellular body water for volume terms.
However, Garonzik et al. [19] suggested that only a fraction
of the CMS dose that was not excreted unchanged in urine
was eventually converted into colistin. This is probably
correct, because some of the partially sulphomethylated
34 Clinical Microbiology and Infection, Volume 18 Number 1, January 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 30–39
derivatives are likely to be excreted in urine before being
converted into colistin. How much of the CMS dose not
excreted unchanged in urine is not converted into colistin is
difﬁcult to assess. However, it is important to mention that
these two articles, published almost simultaneously, used the
same terminology (fm) with different meanings. In our article,
fm refers to the fraction of the CMS dose that was not
excreted unchanged in urine [22], whereas in Garonzik et al.
[19], fm corresponds to the unknown fraction of the non-
renal clearance of CMS that actually forms colistin, which we
implicitly assumed to be equal to one. We therefore suggest
keeping the terminology used by our colleagues, and not
using fm as we did, but instead using 1 – fe, and we propose
a new schematic representation of CMS and colistin dis-
tribution (Fig. 3) to summarize this terminology issue. Note
that, with this terminology, the fraction of the CMS dose
eventually converted into colistin is not equal to fm, and it
was named fmcoli in order to avoid further confusion, with
fmcoli = (1 ) fe) · fm.
The last modern pharmacokinetic study to our knowledge
was conducted by our group, and combined data collected in
healthy volunteers with those obtained in critical-care
patients (n = 32 for 242 samples analysed) treated in a real
clinical setting. The results have not yet been published, but
were presented at the last ECCMID meeting in Milan
(Gre´goire et al., 21st ECCMID, 2011, 804pp.). Patients had
various levels of renal function, from normal to severely
impaired, but none required extrarenal replacement. The
dosing regimen varied between 0.5 and 4 MIU/8 h, with a
median of 2 MIU/8 h. Colistin concentrations ranged from
below the limit of quantiﬁcation to 6.4 mg/mL, with a median
of 1.1 mg/mL. Pharmacokinetic parameters were estimated
with a population approach, using the previously reported
pharmacokinetic model with two compartments for CMS
and one compartment for colistin [17,19]. The pharmacoki-
netic parameters estimated in critically ill patients are pre-
sented in Table 1, and are consistent with those presented
in the same table and obtained by others during these recent
modern pharmacokinetic studies. It was conﬁrmed that CMS
renal clearance was related to CrCL, and, interestingly, the
estimated colistin clearance in this study (CLcoli = 33.4 mL/
min) had a tendency to be lower than previously reported
values, in particular in healthy volunteers (typical value for
CLcoli of 48.7 mL/min).
Altogether, these recent modern pharmacokinetic studies
have provided a large and important amount of useful infor-
mation. In particular, Garonzik et al. showed that using CrCL
as a covariate explained about 60% of the variability in the
‘ideal’ maintenance dose of CMS required to achieve a given
target Css,avg. However, 40%, which is about half of the vari-
ability, is still out of control. As a consequence, although a
majority of patients exhibit colistin plasma concentrations at
steady state within the target range, some individuals occa-
sionally present unexpectedly high colistin concentrations, as
observed by Garonzik et al. as well as by ourselves in our
current practice. Attention should now be paid to these
patients, as high colistin plasma concentrations may be
responsible for toxicity. This question will now be investi-
gated from a theoretical standpoint, in order to identify
potential factors responsible for unusually high colistin con-
centrations.
Because colistin concentration ﬂuctuations within a dosing
interval at steady state are limited when CMS is administered
three times daily, as is usually recommended, at least for the
moment, it is essential to understand which pharmacokinetic
parameters determine Css,avg and how these parameters may
be altered in critical-care patients.
By deﬁnition, at steady state, the rate of colistin formation
is equal to its rate of elimination, from which Eqn 3 can be
derived.
fmcoli Dose
s
¼ CLcoli  Css;avg ðEqn3Þ
where fmcoli corresponds to the fraction of the CMS dose
converted into colistin, dose/s the CMS maintenance dose,
and CLcoli the colistin clearance. As this has no impact on
the general reasoning but simpliﬁes the demonstration, it will
be assumed that the fraction of the CMS dose not excreted
unchanged in urine is totally converted into colistin (fm = 1).
CMS
UrineRenal clearance
(fe)
R l l
Urine
Non-renal clearance
(1-fe) Partially
sulfomethylated
derivatives
ena  c earance
Non-renal clearance
(fm) Colistin
Renal
clearance
Urine
Non-renal
clearance Colistin metabolites
FIG. 3. Schematic representation of the disposition of colistin meth-
anesulphonate (CMS) and the colistin generated from it in the body
following intravenous administration of CMS, adapted from the initial
pathway proposed by Li et al. to account for potential incomplete
conversion of partially sulphomethylated derivatives to colistin, possi-
bly owing to urinary excretion of these intermediate compounds,
where fe corresponds to the fraction of the CMS dose excreted
unchanged in urine, and fm to the fraction of non-renally cleared
CMS that actually forms colistin.
CMI Couet et al. Colistin pharmacokinetics 35
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 30–39
Eqn 3 may then be reorganized, leading to Eqn 4, which pre-
dicts Css,avg.
Css;avg¼ CLNR
CLRþCLNR
Dose
s CLcoli ðEqn4Þ
Therefore, Css,avg is determined by two parameters reﬂecting
formation (CMS clearance terms) and a third one character-
izing elimination (colistin clearance). Notably, the colistin vol-
ume of distribution, which is likely to be altered in critical-
care patients, has no effect on Css,avg. Simulations were con-
ducted with parameter values estimated in healthy volunteers
as a starting point [22]. CMS renal clearance, referred to as
CLR, was assumed to be equal to 85% of GFR
(CLR = 0.85 GRF), and CMS non-renal clearance (CLNR) and
colistin clearance were set at 50 mL/min.
Effect of altered CMS renal clearance on Css,avg
Simulations were conducted for various maintenance doses
(1, 2 and 3 MIU every 8 h), and Css,avg was predicted for var-
ious CrCL values as an indicator of changing CMS renal
clearance (Fig. 4). These simulations show that, for an indi-
vidual with normal renal function, the usual upper CMS dos-
ing regimen (3 MIU/8 h) would lead to a Css,avg close to
2 mg/mL. It is also apparent from these simulations that
Css,avg could not be higher than approximately 10 mg/mL,
even in an anuric patient (CrCL = 0 mL/min). However,
these simulations also suggest that a relatively high Css,avg
could be reached in patients with altered renal function, pro-
vided that the CMS dosing regimen was maintained at a sufﬁ-
cient level. As an example, a Css,avg of 4 mg/mL could be
reached in a patient with CrCL equal to 30 mL/min,
provided that the 3 MIU/8 h CMS dosing regimen was
maintained. Therefore, according to these simulations, mod-
erate renal impairment should not be viewed only as causing
a risk of toxicity, owing to overexposure, but also as an
opportunity to reach efﬁcient colistin concentrations. Reduc-
ing CMS doses in patients with renal insufﬁciency according
to the recommendations appearing in product information
before the Garonzik et al. article may not be appropriate.
However, of course, clinical evidence, including careful moni-
toring of toxicity, should support this statement.
Effect of altered CMS non-renal clearance on Css,avg
Non-renal elimination of CMS is poorly understood, and it is
therefore difﬁcult to speculate on between-patient CMS
CLNR variability. However, because CLNR appears in the
numerator and denominator of Eqn 4, the effect of altered
non-renal CMS elimination on Css,avg should be relatively lim-
ited. This was conﬁrmed by simulations conducted for vari-
ous CLNR values from 50 to 25 and 12.5 mL/min.
Furthermore, it is interesting to note that, when CMS non-
renal clearance decreases, Css,avg also decreases. There is
therefore no risk of toxicity caused by overexposure in case
of CMS non-renal clearance impairment (Fig. 5).
Effect of altered colistin clearance on Css,avg
Average colistin concentration at steady state is determined
by the previously described pharmacokinetic parameters
affecting its rate of formation, and also by its own clearance,
as indicated by Eqn 4. Because colistin is presumably charac-
terized by a low hepatic extraction ratio, impaired enzymatic
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FIG. 4. Simulated colistin concentrations at steady state (Css,avg) as a
function of creatinine clearance (CrCL) following various mainte-
nance doses of colistin methanesulphonate (CMS) (1 MIU/8 h
(green), 2 MIU/8 h (fuchsia), and 3 MIU/8 h (blue)), assuming that
CMS renal clearance equals 0.85 CrCL, with CMS non-renal clear-
ance and colistin clearance equal to 50 mL/min.
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FIG. 5. Simulated colistin concentrations at steady state (Css,avg) as a
function of creatinine clearance (CrCL) following a maintenance dose
of colistin methanesulphonate (CMS) equal to 3 MIU/8 h and for dis-
tinct values of CMS non-renal clearance (50 mL/min (top), 25 mL/
min (middle), and 12.5 mL/min (bottom)), assuming that CMS renal
clearance equals 0.85 CrCL, and colistin clearance equals 50 mL/min.
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activity is among the factors that may have an effect on its
clearance, but experimental data are lacking and probably dif-
ﬁcult to obtain. Therefore, simulations are of great interest
for predicting the potential effect of reduced colistin clear-
ance on Css,avg. These were conducted for CLcoli values cor-
responding to 50% and 25% of the estimated value in healthy
volunteers, i.e. 25 mL/min and 12.5 mL/min, respectively, and
the results are shown in Fig. 6a,b. It is clear from these simu-
lations that impaired colistin elimination may be responsible
for relatively high Css,avg values. As an example, Css,avg in the
order of 10 mg/mL, which could not be reached in healthy
volunteers (Fig. 4), would be obtained in a patient with rela-
tively moderately impaired renal elimination (CrCL = 60 mL/
min) but with a relatively more important reduction in CLcoli
(12.5 mL/min, corresponding to 25% of the value estimated
in healthy volunteers). Therefore, although colistin clearance
is presently not well characterized, except for being almost
exclusively non-renal, this parameter is critical, not only
because high and potentially toxic Css,avg values could be
obtained in patients with seriously impaired colistin clear-
ance, but also because it is difﬁcult to predict. It was there-
fore interesting to compare these simulation results with
real-life observations.
Case reports of unexpectedly high Css,avg in critical-care
patients
A ﬁrst patient treated with multidrug therapy including CMS
(3 MIU/8 h) for an infection caused by multidrug-resistant
Gram-negative bacteria exhibited generalized seizures, lead-
ing a posteriori to colistin plasma concentration determination
[23]. CrCL was estimated to be 50 mL/min. According to
Fig. 3, i.e. considering that colistin clearance in this patient
should be comparable to that in healthy volunteers, Css,avg
should be close to 3 mg/mL, when in fact it was determined
by LC-MS/MS to be 8.1 mg/mL. This difference could be
explained by lower than expected colistin clearance in this
patient. Notably, a reduction by half of colistin clearance as
compared with that of healthy volunteers (CLcoli reduced
from 50 to 25 mL/min) would predict an average steady-
state colistin concentration close to the measured value in
this patient (Fig. 6a).
A second patient with cystic ﬁbrosis who had received a
lung transplant had a much lower CrCL, estimated to be
14 mL/min, indicating considerably reduced renal function.
The CMS dosing regimen was ﬁxed at 1.5 MIU/8 h. Once
again, according to Fig. 4, Css,avg should be within 2–4 mg/mL.
In fact, it was determined to be 10 mg/mL, again suggesting a
difﬁcult-to-predict reduction in colistin clearance in this
patient.
Perspectives
These recent pharmacokinetic data collected by various
groups, which are essentially consistent with each other,
raise a number of issues. According to the limited ﬂuctua-
tions in colistin plasma concentration vs. time proﬁles at
steady state, the usual CMS dosing regimen (three times
daily) does not seem to be rational. Reducing the number
of daily administrations would decrease the workload in
critical-care units, reducing the risk of errors, and the dif-
ference in terms of colistin concentration vs. time proﬁles
between 3 MIU/8 h and 4.5 MIU/12 h, and to a better
degree 9 MIU/24 h, should be relatively limited (Fig. 7b).
Therefore, with the same daily dose, two daily administra-
tions could be more appropriate than three. However, CMS
concentration vs. time proﬁles should also be considered.
The CMS peak, in particular, would not be very different
between the 3 MIU/8 h and 4.5 MIU/12 h schedules, but
would be much higher after once-daily administration at the
same daily dose, i.e. 9 MIU/24 h (Fig. 7a). Notably, the CMS
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FIG. 6. Simulated colistin concentrations at steady state (Css,avg) as a
function of creatinine clearance (CrCL) following various mainte-
nance doses of CMS (1 MIU/8 h (green), 2 MIU/8 h (fuchsia), and
3 MIU/8 h (blue)), assuming that CMS renal clearance equals
0.85 CrCL and CMS non-renal clearance equals 50 mL/min, for colis-
tin clearance equal to 25 mL/min (a) and 10 mL/min (b).
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volume of distribution should determine peak values and
should therefore be taken into consideration in this respect.
A high CMS peak may have consequences in terms of toler-
ability and even toxicity. Therefore, although reducing the
number of CMS doses appears to be a real possibility on a
pharmacokinetic basis, clinical evidence should ﬁrst be pro-
vided before any decision is made.
Another interesting question concerns the potential ben-
eﬁt of colistin concentration monitoring. The recent phar-
macokinetic studies reviewed in this article suggest that
colistin concentrations are probably most frequently lower
than targeted. This was clear in our ongoing pharmacoki-
netic study in 33 critical-care patients, in which Css,avg ran-
ged from below the limit of quantiﬁcation to 6.4 mg/mL,
with a median of 1.1 mg/mL. In this study, dosing regimens
were selected by clinicians on the basis of their own expe-
rience. It appeared that CMS dosing regimens were reduced
in patients with mild to moderate renal impairment, when
in fact this may not have been appropriate. Therefore, the
general message would be to encourage clinicians to change
their habits and prescribe higher doses of CMS. However,
colistin concentrations in the order of 10 mg/mL may occa-
sionally be observed. Impaired enzymatic activity caused by
liver disease or drug–drug interactions could perhaps be
responsible for reduced colistin clearance and, in turn, high
average steady-state concentrations. Unfortunately, these
phenomena are mostly unknown, and colistin clearance
impairment in a particular individual is almost impossible to
predict at present. Therefore, colistin concentration moni-
toring may be advisable to provide security for clinicians
when, at the same time, they are encouraged to increase
CMS dosing regimens.
Because colistin concentration ﬂuctuations are limited
within a dosing interval, especially when CMS is given three
times daily, we believe that one should not try to differenti-
ate between peak and trough concentrations. However,
although a plasma concentration determined at any time
would probably provide an appropriate estimate of Css,avg for
the purposes of drug monitoring, it would be more advisable
to sample immediately before CMS dosing, not only because
this is frequently more convenient from a practical view, but
also, and more importantly, because CMS concentrations
would then be minimal and the risk of colistin concentration
overestimation resulting from post-sampling CMS hydrolysis
would therefore be considerably reduced. Colistin drug
monitoring was recently introduced in our institution, using
a two-step procedure with colistin concentration determina-
tion after 2 or 3 days of treatment to estimate CLcoli in the
patient and readjust the CMS dosing regimen. Most often,
clinicians expected colistin concentrations that were higher
than observed. This is particularly true for clinicians who are
used to relying on microbiological assays for colistin,
because, with the use of these non-speciﬁc assays, artiﬁcially
high and misleading ‘peak concentrations’ are obtained.
In conclusion, tremendous progress has been made
recently in our understanding of the complex colistin phar-
macokinetics following intravenous dosing with CMS in criti-
cal-care patients. It is not yet possible to predict colistin
concentrations in every individual patient with total accuracy.
However, complementary studies are being conducted by
various groups, and rapid progress is expected. The next
step will be to better understand colistin pharmacokinetics–
pharmacodynamics, and to characterize drug–drug interac-
tions both at a pharmacokinetic and at a pharmacokinetic–
pharmacodynamic level, as critical-care patients infected by
multidrug-resistant bacteria are not treated with colistin
alone, but with a mixture of several antibiotics. Therefore,
the challenge is real, but the fog is lifting.
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FIG. 7. Simulations of steady-state colistin methanesulphonate
(CMS) (a) and colistin (b) plasma concentrations vs. time following
administration of the same daily dose of CMS with various dosing
regimens (9 MIU/24 h (red), 4.5 MIU/12 h (blue), and 3 MIU/8 h
(green)), for a typical patient with creatinine clearance set at 60 mL/
min, CMS non-renal clearance and colistin clearance equal to 50 mL/
min, and CMS and colistin Vss set at 15 L.
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